Quick Answer
Regencell Bioscience Holdings Ltd reported Stockholders Equity of $4.86 million for fiscal year 2025.
Regencell Bioscience Holdings Ltd Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $4.86M | -40.9% |
| 2024 | $8.22M | -31.7% |
| 2023 | $12.03M | -29.5% |
| 2022 | $17.07M | +526.9% |
| 2021 | -$4.00M | -50.8% |
| 2020 | -$2.65M | -44.2% |
| 2019 | -$1.84M | -27.0% |
| 2018 | -$1.45M | — |
- Regencell Bioscience Holdings Ltd showed a decrease of -40.9% in Stockholders Equity compared to the prior fiscal year.
- Over the 2018–2025 period, Regencell Bioscience Holdings Ltd’s stockholders equity has grown by 435.8% (from -$1.45 million to $4.86 million).
- The most recent figure is from Regencell Bioscience Holdings Ltd’s fiscal year 2025 report (Form 20-F), filed with the SEC on October 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: